All together, these results demonstrate for the first time the pivotal role of CD271 in melanoma acquired resistance and highlights the role of of TNFα/NF-κB signaling pathway in the maintenance of CD271 expression and cell resistance in BRAFi-treated cells. The gene discussed is TNF; the disease is melanoma.